Were Walid Abi-Saab’s uniQure (QURE) share sales discretionary or pre-planned?

The share sales were pre-planned. A footnote explains they were effected under a sales plan adopted on September 26, 2025 intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

What is notable about the pricing of Walid Abi-Saab’s uniQure (QURE) share sales?

The filing reports weighted-average sale prices, with transactions executed between $25.00 and $25.29 per share. Abi-Saab has undertaken to provide detailed trade-level price breakdowns to the issuer, shareholders, or SEC staff upon request.

uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On May 8, 2026, he sold a total of 45,000 Ordinary Shares in open-market transactions at weighted-average prices around $25.00–$25.29, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.

On the same date, he exercised 25,000 stock options with a $5.59 exercise price, receiving an equal number of Ordinary Shares. After these transactions, he directly held 169,669 Ordinary Shares and 60,500 stock options expiring on March 1, 2034, indicating he retains a substantial equity stake.

Insider Trade Summary 10b5-1

Net Seller: 45,000 shares ($1,127,500)

Net Sell 4 txns

Insider Abi-Saab Walid

Role Chief Medical Officer

Sold 45,000 shs ($1.13M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,000	$0.00	--
Exercise	Ordinary Shares	25,000	$5.59	$140K
Sale	Ordinary Shares	25,000	$25.10	$628K
Sale	Ordinary Shares	20,000	$25.00	$500K

Holdings After Transaction: Stock Option (Right to Buy) — 60,500 shares (Direct, null); Ordinary Shares — 214,669 shares (Direct, null)

Footnotes (1)

The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.

Key Figures

Shares sold tranche 1: 20,000 shares at $25.00 Shares sold tranche 2: 25,000 shares at $25.10 Options exercised: 25,000 shares at $5.59 +3 more

6 metrics

Shares sold tranche 1 20,000 shares at $25.00 Ordinary Shares sold May 8, 2026

Shares sold tranche 2 25,000 shares at $25.10 Ordinary Shares sold May 8, 2026

Options exercised 25,000 shares at $5.59 Stock option exercise price

Shares after transactions 169,669 shares Ordinary Shares held directly after May 8, 2026

Options remaining 60,500 options Stock options following the reported exercise

Option expiration March 1, 2034 Remaining stock options expiry date

Key Terms

Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares, +1 more

5 terms

Rule 10b5-1 regulatory

"intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

05/12/2026 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Abi-Saab Walid

(Last)

(First)

(Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM

1105BP

(City)

(State)

(Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	05/08/2026		M⁽¹⁾		25,000	A	$5.59	214,669	D
Ordinary Shares	05/08/2026		S⁽¹⁾		25,000	D	$25.1⁽²⁾	189,669	D
Ordinary Shares	05/08/2026		S⁽¹⁾		20,000	D	$25	169,669	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.59	05/08/2026		M⁽¹⁾			25,000	⁽³⁾	03/01/2034	Ordinary Shares	25,000	$0	60,500	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.

	/s/ Christian Klemt, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did uniQure (QURE) report for Walid Abi-Saab?

uniQure reported that Chief Medical Officer Walid Abi-Saab sold 45,000 Ordinary Shares and exercised 25,000 stock options. The trades occurred on May 8, 2026 and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many uniQure (QURE) shares did Walid Abi-Saab sell and at what prices?

Walid Abi-Saab sold 20,000 Ordinary Shares at about $25.00 and 25,000 shares at about $25.10. Footnotes state these were weighted-average prices across multiple trades ranging from $25.00 to $25.29 per share.

What stock options did Walid Abi-Saab exercise in the uniQure (QURE) Form 4?

He exercised 25,000 stock options with a $5.59 exercise price, receiving 25,000 Ordinary Shares. The options were granted March 1, 2024, vesting 25% after one year and 6.25% quarterly thereafter until fully vested.

How many uniQure (QURE) shares does Walid Abi-Saab hold after these transactions?

Following the reported transactions, Walid Abi-Saab directly holds 169,669 Ordinary Shares of uniQure. The Form 4 also shows 60,500 stock options remaining outstanding after the option exercise reported in the filing.